Search Results

CSL announced the 2022 Half Year Financial Results for the period ending 31st December 2021, on Wednesday, 16th February 2021 (AEDT)

We announced our 2021 Half Year Financial Results on Thursday, 18th February 2021 (AEDT).

CSL, representing the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor, relentlessly innovates to help ensure patients and people get the treatments they deserve.

Tax positions adopted must be and financial results.

We announced our 2021 Full Year Financial Results for the period ending 30th June 2021 on Wednesday, 18th August 2021 (AEST).

Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

BOARD RESPONSIBILITIES - SIGNIFICANT ANNOUNCEMENTS The Board is responsible for approving all significant planned disclosures to be made to the ASX (such as announcements of financial results, market guidance or major transactions).

The financial results for each half year ended 31 December are generally reported in February each year.

In addition to delivering solid improve the efficiency of our business and the way in which financial results, we made significant contributions in the we help patients.

20th October 2020 Forward looking statements The information in this presentation is current as of the date of this presentation, and includes forward looking statements about CSL Limited and its related bodies corporate's (CSL) financial results and estimates, business prospects and product candidates in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.